WithdrawnPhase 2/3

Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction

Slovakia0Started 2016-07

Plain-language summary

This study is aimed to assess the efficacy of Human derived Transfer factor ( T-lymphocytes homogenate that contains small molecular weight (10 kDa) molecules: various IFNs, ILs, chemokines, endorfins, heat shock proteins) in decreasing rate and/or severity of infections in acute or chronic decompensations of liver cirrhosis and acute on chronic liver failure..

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * admission to hospital at participating liver units or ICUs or internal medicine wards with acute decompensation (AD) of advanced chronic liver disease or acute-on-chronic liver failure according to CLIF - C criteria * ability to provide informed consent, Exclusion Criteria: * disapproval * lymphoproliferative disorders * liver transplantation in the past * pregnancy * suspected. chronic infection in risk locations * CNS * peritoneum * Known virus-related immune deficiency * malignancy * severe heart failure (NYHA \>= III) * severe lung disease (COPD, GOLD\>3)

What they're measuring

Composite endpoint that includes the incidence specified infections:

Timeframe: Two years

Trial details

NCT IDNCT02837939

SponsorMartin Janičko

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07

View on ClinicalTrials.gov More Cirrhosis trials